Redeye comments on Alligator Bioscience’s recently announced strategic pivot and accompanying rights issue. The decision to halt the independent development of the lead clinical asset represents a drastic but rational response to a rapidly changing competitive landscape and ongoing funding constraints. As standalone development within the targeted oncology indication is no longer deemed commercially viable, operations will be significantly scaled back to minimise cash burn. The strategic focus now shifts to preserving the royalty upside of HLX22 - an out-licensed Phase 3 project.
LÄS MER
